SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending as traders anticipate news from an upcoming conference and potential operational updates, focusing on the company's shift towards AI infrastructure and efficient energy use. Community members are actively discussing price targets and potential short squeezes, citing the stock's low float and past volatility. This buzz comes after the company resolved a legal battle with its former CEO, which is now seen as a positive catalyst for its re-emergence.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is plunging amid concerns about rising AI costs and increasing debt, overshadowing otherwise strong cloud growth and backlog. The community is actively debating whether this dip is an overreaction or a sign of deeper problems with Oracle's AI strategy, while some see a buying opportunity, others fear further declines.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential in treating cancers, particularly after positive data in prostate cancer trials, while also citing undervaluation. The community is actively discussing the possibility of a short squeeze given the high short interest. Some also speculate about potential partnerships and acquisitions in the near future! LOAD!

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending as investors debate whether it's a buying opportunity after hitting new lows, driven by concerns about competition and tax-loss harvesting. Community discussions revolve around the potential for a turnaround, the impact of Amazon's growing presence, and frustrations with the company's leadership amidst a significant year-to-date decline. Despite strong financials and AI investments, the stock struggles to gain momentum, leaving investors divided between those anticipating a rebound and those fearing further downside.

Black Titan Corp. was formed for the purpose of effecting a merger between Titan Pharmaceuticals Inc. and TalenTec Sdn Bhd. It intends to explore and identify viable business opportunities. The company was founded on July 11, 2024 and is headquartered in Petaling Jaya, Malaysia.

Black Titan Corp.

BTTC is trending due to positive news around its DAT+ framework, sparking discussions about its potential in the digital asset space. Community members are actively debating the possibility of a significant squeeze, with some expressing concerns about trading halts and market manipulation. The stock's volatile price action and association with the crypto sector are also fueling the conversation.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors anticipate its upcoming Autonomy and AI Day, with discussions focused on the company's technology roadmap and potential advancements in autonomous driving. The community is debating whether the event will be a catalyst for growth or a "sell the news" event, and there is also some skepticism related to competition in the EV sector and historical stock manipulation.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

GEMI is trending due to its derivatives arm, Gemini Titan, securing a CFTC license to launch regulated prediction markets in the U.S., a move celebrated by CEO Tyler Winklevoss. Community chatter highlights the potential for a short squeeze and increased valuation, with some drawing comparisons to prediction market competitors. The license is viewed as a significant catalyst, potentially unlocking substantial growth amid the broader crypto adoption boom.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL is trending due to a recently announced national retail distribution agreement with Walmart, sparking community excitement about increased market reach. Discussions revolve around the potential for a short squeeze, given the stock's low float and high short interest. Some traders are closely watching volume and key price levels, while others express caution about potential volatility.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is experiencing volatility as traders react to a mix of news, including a report of declining funded customers in November and Cantor Fitzgerald's updated overweight rating with a price target of 155. Community discussions revolve around the dip as a buying opportunity versus concerns about trading volumes and market manipulation. The stock's correlation with Bitcoin's price movement and the broader market adds to the uncertainty, despite some anticipating a potential Santa Claus rally.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs ($PL) is trending following positive Q3 earnings, guidance, and a new contract with the U.S. Navy, driving discussions about its growth potential in the space and defense sectors. The community is focused on the company's strong financials and backlog, and its potential as a long-term investment, with some eyeing a breakout towards $20. The recent surge is also attributed to increased interest in space data and infrastructure, with some comparing it to a mini SpaceX.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market Lunai Bioworks Identifies Three...

<ul class="summary-bullets"><li>The company has now proposed an early-stage clinical trial to evaluate the cell therapy.</li><li>Lunai is also advancing additional studies and expanding the clinical reach of its DCCT platform through collaborations with investigators in non-small cell lung cancer and prostate cancer.</li><li>The company is also preparing for formal licensing negotiations and pursuing activities ahead of the commencement of human clinical trials in early 2026.</li></ul><p>&nbsp;</p><p>Shares of Lunai Bioworks (LNAI) jumped 26% in the pre-market session on Tuesday after the company announced that it has secured its first letter of intent (LOI) to license its next-generation immune cell therapy.</p><p>"We are seeing accelerating validation from both researchers and industry partners," <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lunai-bioworks-secures-first-licensing-loi-following-landmark-breakthrough-showing-complete-tumor-regression-in-humanized-cancer-models-302624947.html">said</a> CEO David Weinstein. He added that the early licensing activity reflects growing confidence in the platform's potential to unlock scalable treatments.</p><h2 class="st-heading-2">Data For Cell Therapy</h2><p>The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.</p><p>The company has now proposed an early-stage clinical trial to evaluate the cell therapy, manufactured from healthy donor cells and stored ready-to-use, across several high-risk tumors, including pancreatic cancer, which has a poor survival rate.</p><h2 class="st-heading-2">Plans Ahead</h2><p>Lunai is also advancing additional studies and expanding the clinical reach of its DCCT platform through collaborations with investigators in non-small cell lung cancer and prostate cancer.</p><p>Additionally, it is preparing for formal licensing negotiations and pursuing activities ahead of the commencement of human clinical trials in early 2026.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around LNAI jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/LNAI">LNAI stock</a> is down by 85% this year and by about 75% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-experimental-glp-1-drug-shows-weight-loss-blood-sugar-level-reduction-in-study/cL52hCvREXo">Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

 In this photo illustration, the Lunai Bioworks logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

LNAI Stock Soars Pre-Market After Immune Cell Therapy Gains Licensee Interest 

The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.

Equity

The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.


Top Biotech Stocks To Follow Now - November 5th

Danaher, Vertex Pharmaceuticals, Recursion Pharmaceuticals, Moderna, and Lunai Bioworks are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are...

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Lunai Bioworks Inc.

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$1.17
Prev Close	$1.19
Open	$1.19
Dividend Yield	0.00%
50-Day Moving Average	$1.15
Beta	1.24
Avg. Volume	12.31M
PE Ratio	-0.15

52-Week High	$20.40
52-Week Low	$0.81
Market Capitalization	$27.88M
EPS (Annual)	-$10.78
Price to Book	-2.12
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

LNAI
Lunai Bioworks Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LNAI News

LNAILunai Bioworks Inc.